Testing a new gene therapy injection for wet age-related macular degeneration

Plain-English translation of NCT07007065 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated ·

What is this trial?

This study is testing a new treatment called Surabgene Lomparvovec, which is a gene therapy delivered as an injection into the eye to treat wet age-related macular degeneration (nAMD)—a serious eye disease where abnormal blood vessels grow in the retina and cause vision loss. Researchers want to see if this medication can reduce how often patients need eye injections and help preserve vision over the long term. Some participants will receive the new treatment once, while others will continue receiving the standard treatment they've been using.

Wet macular degeneration currently requires frequent eye injections to slow vision loss, which is burdensome for patients. This trial aims to see if a one-time gene therapy injection could offer a longer-lasting solution and reduce the need for repeated treatments.

Do you qualify?

You likely qualify if…

you are 50 years or older
you have been diagnosed with wet age-related macular degeneration in at least one eye
your eye to be treated has had cataract surgery at least 12 weeks before the study starts
you have received at least 2 anti-VEGF injections in the past 6 months and your doctor confirmed they helped reduce your disease
the abnormal blood vessel growth in your eye is smaller than 10 disc areas (a specific size measurement)

You likely don't qualify if…

you have abnormal blood vessel growth in your eye caused by something other than age-related macular degeneration
you were diagnosed with wet macular degeneration more than 4 years ago
you have bleeding in the back of your eye that covers more than half the affected area or is in the central vision zone
you have large fluid pockets under the retina in the back of your eye that are too big
you have a tear in the pigmented layer at the back of your eye in the central vision area

What participation looks like

If you join this study, you will be randomly assigned to one of three groups: two groups will receive the new gene therapy injection once (at different doses), and one group will continue receiving the standard treatment as needed. You will attend monthly clinic visits for up to 5 years, during which doctors will check your vision, perform eye scans and blood tests, and ask about any side effects you experience. Overall, this trial may require more frequent visits than your usual care.

Testing a new gene therapy injection for wet age-related macular degeneration

What is this trial?

Do you qualify?

What participation looks like

Trial locations(128 sites)